To cite this paper use one of the standards below:
Dystroglycanopathies are muscular disorders associated to hypoglycosylation of α-dystroglycan (hgα-DG)[1]. Their diagnosis is still a critical issue since there are not specific antibodies available for hgα-DG [2]. Hence, we synthesized a hypoglycosylated α-DG mimetic glycopeptide (glycopeptide-1) to generate mouse polyclonal antibodies (IP-pAbs) and fragment of human recombinant antibodies. Variable heavy (VH) and variable light (VL) domains were selected by Phage Display, identified by NGS, and analyzed by ATTILA platform. The best-selected VH and VL domains were cloned (GpαDG1-scFv) and expressed in E. coli. IP-pAbs and GpαDG1-scFv recognized the glycopeptide-1. The peptide portion of glycopeptide-1 partially inhibited the anti-GpαDG1-scFv/glyccopeptide-1 interaction, suggesting that it involves the amino acids and the sugar portion from glycopeptide-1. In silico analysis suggested that this interaction occurs through hydrogen bonds and hydrophobic contacts involving amino acids from anti-GpαDG1-scFv with arginine-8 and α-mannose from glycopeptide-1. This work can help the development of novel strategies to dystroglycanopathies diagnosis.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper